Recro Pharma Inc (REPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Recro Pharma Inc (Recro Pharma) is a specialty pharmaceutical company that focuses on developing novel products for commercialization in hospital and other acute care settings and provides contract development and manufacturing (CDMO) services. The company is developing IV/IM Meloxicam, a proprietary, rapid-onset, long-acting preferential COX-2 inhibitor for the treatment of acute post-operative pain and acute pain; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine for the treatment of peri-procedural pain and cancer breakthrough pain. It also develops and manufactures pharmaceutical products based on its proprietary delivery technologies for commercial partners. Recro Pharma is headquartered in Malvern, Pennsylvania, the US.

Recro Pharma Inc (REPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recro Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Recro Pharma Acquires Certain Assets from Alkermes 10
Licensing Agreements 12
Recro Pharma Enters into Licensing Agreement with Cornell University 12
Pernix Therapeutics Enters into Licensing Agreement with Recro Pharma 13
Equity Offering 14
Recro Pharma Plans to Raise up to USD40 Million in Public Offering of Shares 14
Recro Pharma Plans to Raise USD20 Million in Public Offering of Shares 15
Recro Pharma Raises USD40 Million in Public Offering of Shares 16
Recro Pharma Raises USD7.8 Million in Private Placement of Shares 18
Recro Pharma Raises USD15 Million in Public Offering of Shares 19
Recro Pharma Raises USD16 Million in Private Placement of Shares 21
Recro Pharma Completes IPO For US$34.5 Million 22
Recro Pharma Inc - Key Competitors 23
Recro Pharma Inc - Key Employees 24
Recro Pharma Inc - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2018: Recro Pharma Reports third quarter 2018 financial results raising guidance for CDMO business for 2018 26
Aug 07, 2018: Recro Pharma announces second quarter 2018 financial results 28
May 09, 2018: Recro Pharma Reports First Quarter 2018 Financial Results 30
Feb 27, 2018: Recro Pharma Announces Year End 2017 Financial Results 32
Nov 09, 2017: Recro Pharma Reports Third Quarter 2017 Financial Results 34
Aug 10, 2017: Recro Pharma Reports Second Quarter 2017 Financial Results 36
May 11, 2017: Recro Pharma Reports First Quarter 2017 Financial Results 38
Mar 06, 2017: Recro Pharma Reports Year End 2016 Financial Results 40
Corporate Communications 42
Jun 06, 2017: Recro Pharma Appoints Ryan D. Lake as Senior Vice President of Finance and Chief Accounting Officer 42
Mar 06, 2017: Recro Pharma appoints new board member 43
Clinical Trials 44
Apr 30, 2018: Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List Of Tables


Recro Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recro Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recro Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Recro Pharma Acquires Certain Assets from Alkermes 10
Recro Pharma Enters into Licensing Agreement with Cornell University 12
Pernix Therapeutics Enters into Licensing Agreement with Recro Pharma 13
Recro Pharma Plans to Raise up to USD40 Million in Public Offering of Shares 14
Recro Pharma Plans to Raise USD20 Million in Public Offering of Shares 15
Recro Pharma Raises USD40 Million in Public Offering of Shares 16
Recro Pharma Raises USD7.8 Million in Private Placement of Shares 18
Recro Pharma Raises USD15 Million in Public Offering of Shares 19
Recro Pharma Raises USD16 Million in Private Placement of Shares 21
Recro Pharma Completes IPO For US$34.5 Million 22
Recro Pharma Inc, Key Competitors 23
Recro Pharma Inc, Key Employees 24
Recro Pharma Inc, Subsidiaries 25

List Of Figures


Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Recro Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Recro Pharma Inc (REPH) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Recro Pharma Inc (Recro Pharma) is a specialty pharmaceutical company that focuses on developing novel products for commercialization in hospital and other acute care settings and provides contract development and

USD 250 View Report

Recro Pharma Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Recro Pharma Inc Company Profile is a detailed strategic and analytical report on Recro Pharma Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Avisa Pharma Inc - Product Pipeline Analysis, 2019 Update

Avisa Pharma Inc (Avisa Pharma) is a medical device company that develops breath tests system for the diagnosis of pulmonary infections. The company provides product such as avisa breath test

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available